Showing results (41-50 of 159) with videos related to

Sort By:
Pageof 16
American Journal of Hematology|November 16, 2017
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemiaJessica K Altman, James M Foran, Keith W Pratz, et al.
Blood|August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
British Journal of Haematology|July 28, 2006
Constitutively activated FLT3 phosphorylates BAD partially through pim-1Kyu-Tae Kim, Mark Levis, Donald Small
Pharmacoeconomics|June 13, 2022
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer PerspectiveKeith W Pratz, Xinglei Chai, Jipan Xie, et al.
Haematologica|October 13, 2022
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemiaKeith W Pratz, Jason Kaplan, Moshe Levy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2019
BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid MalignanciesWeijie Poh, Robert L Dilley, Alison R Moliterno, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2014
Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemiaMichael R Grunwald, Li-Hui Tseng, Ming-Tseh Lin, et al.
Blood|May 6, 2004
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effectsMark Levis, Rosalyn Pham, B Douglas Smith, et al.
Blood Advances|April 29, 2021
Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysisDavid J Young, Bao Nguyen, Ruiqi Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological MalignanciesShailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, et al.
Pageof 16